Small Company Offering and Sale of Securities Without Registration (d)
13 Noviembre 2020 - 5:07AM
Edgar (US Regulatory)
o
NoneEntity Type | 0001643301 | Makkanotti Group Corp. |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
Name of Issuer |
Cure Pharmaceutical Holding Corp. |
Jurisdiction of Incorporation/Organization |
DELAWARE |
|
Year of Incorporation/Organization |
|
x
| Over Five Years Ago |
|
o
| Within Last Five Years (Specify Year) | |
|
o
| Yet to Be Formed | |
2. Principal Place of Business and Contact Information |
Name of Issuer | |
Cure Pharmaceutical Holding Corp. | |
Street Address 1 | Street Address 2 |
1620 BEACON PLACE | |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
OXNARD | CALIFORNIA | 93033 | 805-824-0410 |
Last Name | First Name | Middle Name |
Davidson | Robert | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Bell | John | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Chung | Lauren | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Goldin | Anya | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Held | Josh | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
King-Shaw | Ruben | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Salkind | Gene | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Yuan | William | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Duitch | Nancy | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Redard | Mike | |
Street Address 1 | Street Address 2 |
1620 Beacon Place | |
City | State/Province/Country | ZIP/Postal Code |
Oxnard | CALIFORNIA | 93033 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
o
| Agriculture | | Health Care |
o
| Retailing |
| Banking & Financial Services | |
o
| Biotechnology |
o
| Restaurants |
|
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
|
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
|
o
| Investing | |
x
| Pharmaceuticals | |
o
| Telecommunications |
|
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
|
o
| Pooled Investment Fund
| | | | | Travel |
|
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| Real Estate | |
o
| Lodging & Conventions |
|
o
| Commercial | |
o
| Tourism & Travel Services |
|
o
| Construction | |
o
| Other Travel |
|
o
| REITS & Finance |
o
| Other |
|
o
| Residential | |
|
o
| Other Real Estate | |
o
| Business Services | |
| Energy | |
|
o
| Coal Mining | |
|
o
| Electric Utilities | |
|
o
| Energy Conservation | |
|
o
| Environmental Services | |
|
o
| Oil & Gas | |
|
o
| Other Energy | |
Revenue Range | Aggregate Net Asset Value Range |
o
| No Revenues |
o
| No Aggregate Net Asset Value |
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
o
| Over $100,000,000 |
o
| Over $100,000,000 |
x
| Decline to Disclose |
o
| Decline to Disclose |
o
| Not Applicable |
o
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
|
o
| Investment Company Act Section 3(c) |
x
| New Notice | Date of First Sale | 2020-10-30 |
o
| First Sale Yet to Occur |
Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
9. Type(s) of Securities Offered (select all that apply) |
o
| Pooled Investment Fund Interests |
o
| Equity |
o
| Tenant-in-Common Securities |
x
| Debt |
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
|
Clarification of Response (if Necessary) | |
|
Minimum investment accepted from any outside investor | $ 0 USD |
Recipient | Recipient CRD Number |
o
| None |
Axiom Capital Management, Inc. | 265801 |
(Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| |
Street Address 1 | Street Address 2 |
350 Fifth Avenue, Suite 5420 | |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10118 |
State(s) of Solicitation |
o
| All States |
o
| Foreign/Non-US |
CALIFORNIA |
13. Offering and Sales Amounts |
Total Offering Amount | $ 11500000 USD |
o
Indefinite |
Total Amount Sold | $ 11500000 USD | |
Total Remaining to be Sold | $ 0 USD |
o
Indefinite |
|
Clarification of Response (if Necessary) |
For further explanation, please see the Current Report on Form 8-K filed by the Issuer on November 2, 2020. |
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
| |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 1 |
15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 0 USD |
o
| Estimate |
Finders' Fees | $ 306000 USD |
x
| Estimate |
|
Clarification of Response (if Necessary) |
Placement agent fee. This amount may increase up to an additional $480,000 upon achievement of certain milestones. |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| $ 0 USD |
o
Cure Pharmaceutical (PK) (USOTC:CURR) Gráfica de Acción Histórica De May 2024 a Jun 2024
Cure Pharmaceutical (PK) (USOTC:CURR) Gráfica de Acción Histórica De Jun 2023 a Jun 2024
Real-Time news about Cure Pharmaceutical Holding Corporation (PK) (OTCMarkets): 0 recent articles
Más de Cure Pharmaceutical Holding Corp. Artículos de Noticias
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
|